MaxCyte, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Synthesis Technologies, Production Processes
    • Drug Discovery Technologies
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
  • Services

Other Names/Subsidiaries

  • CARMA Cell Therapies
  • SeQure Dx
See more in Biomedtracker

Latest on MaxCyte, Inc.

Scrip

Deal Watch: FTC Keeps Current Merger Guidelines In Place, For Now

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Trump Appointee Ferguson Keeps Biden-E

Scrip

Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry

 
• By Eleanor Malone

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

Scrip

Deal Watch: A Closer Look At Boehringer Ingelheim’s Partnering Strategy

 
• By Joseph Haas, Vibha Ravi, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim GmbH is closely

Scrip

Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout

 
• By Joseph Haas, Vibha Ravi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck KGaA Pays $600m For Transfection